ReviewSeminars in nephrology2017
Evolution of Cardiovascular Disease During the Transition to End-Stage Renal Disease.
Review in Seminars in nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Serum Osteoprotegerin Is Associated Independently with Peripheral Arterial Stiffness in Chronic Kidney Disease.Diagnostics (Basel, Switzerland) · 2026Article
- SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art.Clinical kidney journal · 2026Review
- Zinc alleviates vascular calcification by activating ERK1/2-mediated autophagy.Scientific reports · 2025Article
- SerumLife (Basel, Switzerland) · 2025Article
- Article
- Risk factors for and a preliminary prediction model of coronary artery calcification in patients beginning hemodialysis.European journal of medical research · 2025Article
- Decreased Serum Decorin Levels Are Correlated with Aortic Stiffness as Assessed Using Carotid-Femoral Pulse Wave Velocity in Patients with Peritoneal Dialysis.Life (Basel, Switzerland) · 2025Article
- Evaluating the Prophylactic and Nephroprotective Effects of Vitamin D and Metformin in Diabetic Nephropathy.Oxidative medicine and cellular longevity · 2025Article
- Cerebrovascular Disease Hospitalization Rates in End-Stage Kidney Disease Patients with Kidney Transplant and Peripheral Vascular Disease: Analysis Using the National Inpatient Sample (2005-2019).Healthcare (Basel, Switzerland) · 2024Article
- Associated factors of osteoporosis and vascular calcification in patients awaiting kidney transplantation.International urology and nephrology · 2023Article
- Relationship between the triglyceride-glucose index and coronary artery calcification in asymptomatic, non-diabetic patients undergoing maintenance hemodialysis.Renal failure · 2023Observational
- Klotho and lean mass as novel cardiovascular risk factors in hemodialysis patients.Clinical kidney journal · 2023Article
- Predictors of coronary artery calcification and its association with cardiovascular events in patients with chronic kidney disease.Renal failure · 2021Article
- Coronary Artery Disease in Chronic Kidney Disease: Need for a Heart-Kidney Team-Based Approach.European cardiology · 2021Review
- Article
- Relationship between arterial stiffness and chronic kidney disease in patients with primary hypertension.Journal of human hypertension · 2020Article
- Reno-protective effects of oral alkalizing agents in chronic kidney disease with aciduria: protocol for a randomized cohort study.BMC nephrology · 2020Article
- Progression of Aortic Arch Calcification Is Associated with Overall and Cardiovascular Mortality in Hemodialysis.Disease markers · 2020Article
- Association of the kidney allocation system with dialysis exposure before deceased donor kidney transplantation by preemptive wait-listing status.Clinical transplantation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). The rate of death in incident dialysis patients remains high. This has led to interest in the study of the evolution of CVD during the critical transition period from CKD to ESRD. Understanding the natural history and risk factors of clinical and subclinical CVD during this transition may help guide the timing of appropriate CVD therapies to improve outcomes in patients with kidney disease. This review provides an overview of the epidemiology of subclinical and clinical CVD during the transition from CKD to ESRD and discusses clinical trials of CVD therapies to mitigate risk of CVD in CKD and ESRD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.